Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueInventory Average

RedHill Biopharma (RDHL) EBITDA Margin (2016 - 2023)

Historic EBITDA Margin for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to 2992.87%.

  • RedHill Biopharma's EBITDA Margin rose 29290400.0% to 2992.87% in Q2 2023 from the same period last year, while for Jun 2023 it was 158.47%, marking a year-over-year increase of 1809800.0%. This contributed to the annual value of 181.69% for FY2024, which is 3972600.0% down from last year.
  • RedHill Biopharma's EBITDA Margin amounted to 2992.87% in Q2 2023, which was up 29290400.0% from 808.0% recorded in Q1 2023.
  • RedHill Biopharma's 5-year EBITDA Margin high stood at 2992.87% for Q2 2023, and its period low was 4585.97% during Q4 2019.
  • For the 5-year period, RedHill Biopharma's EBITDA Margin averaged around 40.56%, with its median value being 17.35% (2022).
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 39894700bps in 2020, then plummeted by -17358400bps in 2021.
  • Over the past 5 years, RedHill Biopharma's EBITDA Margin (Quarter) stood at 4585.97% in 2019, then surged by 87bps to 596.5% in 2020, then skyrocketed by 81bps to 110.43% in 2021, then surged by 74bps to 29.14% in 2022, then skyrocketed by 10372bps to 2992.87% in 2023.
  • Its last three reported values are 2992.87% in Q2 2023, 808.0% for Q1 2023, and 29.14% during Q4 2022.